KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation
Archives of Biochemistry and Biophysics · 2023
DOI: 10.1016/j.abb.2023.109551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2023. Verfasst von Lina Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, 45…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Commission of Henan Province, Department of Science and Technology of Henan Province.
Abstract (Originalsprache)
Docetaxel is a first-line chemotherapy drug for castration-resistant prostate cancer (CRPC); yet, some CRPC patients develop docetaxel drug resistance. Cabazitaxel is approved in the post-docetaxel treatment setting. However, recent studies suggested cross-resistance between the development of drug resistance and current treatments. In this study, we used docetaxel-resistant cell lines DU145/DTX50 and PC-3/DTX30 to measure the responses to cabazitaxel. Our findings demonstrated that docetaxel resistance could lead to cross-resistance to cabazitaxel. After docetaxel-resistant cells were treated with cabazitaxel, transcriptome analysis was performed, and the results were analyzed in combination with survival analysis and correlation analysis with Gleason score to screen the cross-resistance genes. The continuously increased expression of kinesin family member 14 (KIF14) was identified as the main cause of cross-resistance to cabazitaxel in docetaxel-resistant cells. Silencing the expression of KIF14 could restore the sensitivity of resistant PCa cells to docetaxel and cabazitaxel, attenuate proliferation and promote apoptosis of the resistant PCa cells. Notably, the depressed expression of KIF14 inhibited the phosphorylation of Akt located downstream. In summary, KIF14 mediates the cross-resistance between docetaxel and cabazitaxel, and targeting KIF14 could be an effective measurement for reversing docetaxel or cabazitaxel chemotherapy failure or enhancing the anti-tumor effects of docetaxel or cabazitaxel.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, 450053, Henan, China.
- Department of Oncology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, 450053, Henan, China. Electronic address: shundongcang@zzu.edu.cn.
Förderung
- Health Commission of Henan Province
- Department of Science and Technology of Henan Province
Zitieren
APA
Liu, L., Li, M., Zhang, J., Xu, D., Guo, Y., Zhang, H., & Cang, S. (2023). KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2023.109551
Vancouver
Liu L, Li M, Zhang J, Xu D, Guo Y, Zhang H, et al. KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation. Archives of Biochemistry and Biophysics. 2023. doi:10.1016/j.abb.2023.109551
BibTeX
@article{Liu2023,
author = {Liu, Lina and Li, Mengyuan and Zhang, Junshuo and Xu, Dengfei and Guo, Yan and Zhang, Hui and Cang, Shundong},
title = {KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation},
journal = {Archives of Biochemistry and Biophysics},
year = {2023},
doi = {10.1016/j.abb.2023.109551}
}
EUVIMED